What is GLP3-RT?
GLP3-RT refers to retatrutide, an investigational peptide developed by Eli Lilly. There is no official “GLP-3 receptor.” The “GLP-3” or “GLP3-RT” label is informal shorthand used in research and peptide communities because the molecule activates three receptors:
- GLP-1 receptor (appetite and insulin regulation)
- GIP receptor (incretin amplification)
- Glucagon receptor (energy expenditure and fat oxidation)
This triple-agonist profile distinguishes it from earlier generations of incretin-based peptides and has driven significant research attention.
How GLP3-RT Works – Mechanism of Action
GLP3-RT is a 39-amino-acid peptide with a fatty-acid side chain that extends its duration of action. By activating GLP-1 and GIP receptors, it supports appetite control and glucose-dependent insulin secretion. Concurrent glucagon receptor activation promotes increased energy expenditure and hepatic fat metabolism — a combination not present in dual agonists. This multi-pathway approach is why retatrutide has shown robust results in clinical-stage trials.
Key Research Findings
Published Phase 2 data (NEJM) demonstrated mean body-weight reductions of up to 24.2% at the highest dose over 48 weeks, along with reductions in liver fat. Subsequent Phase 3 TRIUMPH program results have confirmed substantial weight loss (often exceeding 20% at higher doses), improved glycemic control in participants with type 2 diabetes, and benefits in related conditions such as knee osteoarthritis and obstructive sleep apnea in specific subgroups.
These findings position GLP3-RT as a valuable research tool for laboratories studying next-generation metabolic interventions. Note: Retatrutide remains investigational and is not approved by the FDA or any regulatory body for human use.
Comparison Table
| Nickname | Receptors Targeted | Example Compound | Status |
|---|---|---|---|
| GLP-1 | GLP-1 only | Semaglutide | FDA approved |
| Dual (GLP-2) | GLP-1 + GIP | Tirzepatide | FDA approved |
| GLP3-RT | GLP-1 + GIP + Glucagon | Retatrutide | Investigational |
Product Features & Quality Assurance
Our GLP3-RT is supplied as high-purity lyophilized powder (≥99% by HPLC), third-party tested, and accompanied by a Certificate of Analysis (COA). Available in multiple vial sizes to suit different research protocols. Strictly intended for laboratory and in-vitro research use only. Not for human or veterinary consumption.
Why Researchers Choose Our GLP3-RT
- Independently verified purity and identity
- Transparent batch testing and COA
- Consistent quality for reproducible experiments
- Proper storage and handling guidance
- Focus on research integrity and compliance





Reviews
There are no reviews yet.